Abstract
Macrophages activated by macrophage-colony stimulating factor (M-CSF) are potent immune effector cells and can mediate both in vitro cytotoxicity and antitumor effects in vivo. A Phase I trial combining M-CSF with R24, a mouse monoclonal antibody against GD3 ganglioside that has been shown to localize to melanoma tumors, induce inflammation at tumor sites, and result in major tumor responses in some patients with melanoma was performed. Nineteen patients with metastatic melanoma received a 14-day continuous intravenous infusion of 80 micrograms/kg/day of recombinant human M-CSF. R24 was administered daily by intravenous infusion on days 6-10 at doses of 1, 3, 10, 30, and 50 micrograms/m2/day. All patients developed pruritus and urticaria; 13 patients developed transient thrombocytopenia less than 100,000/mm3. The maximum tolerated dose was not reached. All patients developed a monocytosis characterized by increased expression of the antigen HLA-DR and decreased expression of CD14, a phenotype reported to represent a subpopulation of monocytes active in mediating antibody-directed cellular cytotoxicity. Other biologic effects of treatment included marked but transient decreases in total cholesterol, low density lipoprotein, and ...Continue Reading
References
Oct 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M G SandaM T Lotze
Feb 1, 1992·Journal of Immunotherapy·K W ZamkoffA R Rudolph
Jun 1, 1992·Proceedings of the Society for Experimental Biology and Medicine·N YamadaM Kawakami
Apr 1, 1992·Atherosclerosis·I InoueY Watanabe
Jul 1, 1992·Journal of Immunotherapy·B G RedmanE Groves
Aug 1, 1989·The Journal of Experimental Medicine·D H Munn, N K Cheung
Oct 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vadhan-RajA N Houghton
Mar 1, 1988·European Journal of Immunology·M GidlundH Wigzell
Jan 1, 1981·Cancer·A B MillerA Winkler
Nov 15, 1993·Cancer·M N SirottA N Houghton
Jan 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·R G SchaubS K Clinton
Aug 1, 1993·The Journal of Clinical Investigation·T InabaN Yamada
Citations
Aug 30, 2000·International Journal of Cancer. Journal International Du Cancer·G ZengR K Yu
Oct 31, 2000·Journal of Cellular Physiology·S CoralM Maio
Jan 1, 1996·Springer Seminars in Immunopathology·R GruberG Riethmüller
Nov 20, 1998·Medical Oncology·R K AlpaughJ P Dutcher
Sep 25, 2001·Comprehensive Therapy·K Kramer, N K Cheung
Nov 22, 1997·Current Opinion in Immunology·A M Scott, S Welt
Mar 14, 2003·Critical Reviews in Oncology/hematology·Timothy M Pawlik, Vernon K Sondak
Aug 31, 2000·Surgery·J SoteloO Arrieta
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·H C MaguireM J Mastrangelo
Apr 22, 1999·Hybridoma·J QiuT Kieber-Emmons
Jul 17, 1999·Journal of Cutaneous Pathology·M WeichenthalE W Breitbart
May 17, 2003·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Pam FredmanThomas Brezicka
Jul 20, 2010·Immunotherapy·Richard E BeatsonJoy M Burchell
Apr 30, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E M H A de Kleijn, C J A Punt
Aug 17, 2012·Future Oncology·Catherine RabuLindy Durrant
Mar 7, 2002·International Reviews of Immunology·G Cunto-AmestyT Kieber-Emmons
Sep 19, 2008·Cancer·Marie-France DemierreVernon K Sondak
Oct 10, 2006·Veterinary Immunology and Immunopathology·R J MilnerJ Farese
Jun 16, 2016·Pediatric Blood & Cancer·Konstantin DobrenkovNai-Kong V Cheung
Jul 6, 2019·Frontiers in Oncology·Dana L CaseyNai-Kong V Cheung
May 20, 2003·British Journal of Haematology·Kraig AbramsRichard A Nash
Mar 30, 2004·The Journal of Biological Chemistry·Wei ZouHarold J Jennings
Feb 15, 1997·Medizinische Klinik·F Hartmann, M Pfreundschuh
Jul 27, 1999·International Journal of Cancer. Journal International Du Cancer·H FukumotoN Saijo
Feb 22, 2002·Experimental Biology and Medicine·Yasuhiro KohKazuto Nishio